Pfizer drug shows 40% reduction in breast cancer progression risk

March 17, 2026 6:45 AM

Pfizer Inc. (NYSE: PFE) announced that its experimental drug atirmociclib met the primary endpoint in a Phase 2 clinical trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found